temozolomide has been researched along with Leukemia, Myelogenous, Chronic, BCR-ABL Positive in 5 studies
Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Twenty patients (16 with acute myelogenous leukemia, two with acute lymphoblastic leukemia, and two with chronic myelogenous leukemia in blastic phase) received 43 cycles of temozolomide." | 5.10 | Phase I study of temozolomide in relapsed/refractory acute leukemia. ( Ahmed, T; Baskind, P; Liu, D; Loughran, T; Seiter, K; Siddiqui, A, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Seiter, K | 1 |
| Liu, D | 1 |
| Loughran, T | 1 |
| Siddiqui, A | 1 |
| Baskind, P | 1 |
| Ahmed, T | 1 |
| De Vita, S | 1 |
| De Matteis, S | 1 |
| Laurenti, L | 1 |
| Chiusolo, P | 1 |
| Reddiconto, G | 1 |
| Fiorini, A | 1 |
| Leone, G | 1 |
| Sica, S | 1 |
| Katsoulas, A | 1 |
| Rachid, Z | 1 |
| McNamee, JP | 1 |
| Williams, C | 1 |
| Jean-Claude, BJ | 1 |
| Deans, B | 1 |
| Tisdale, MJ | 1 |
| Zucchetti, M | 1 |
| Catapano, CV | 1 |
| Filippeschi, S | 1 |
| Erba, E | 1 |
| D'Incalci, M | 1 |
1 trial available for temozolomide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Phase I study of temozolomide in relapsed/refractory acute leukemia.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Dacarbazine; Dose-Response Relationship, Drug; Drug | 2002 |
4 other studies available for temozolomide and Leukemia, Myelogenous, Chronic, BCR-ABL Positive
| Article | Year |
|---|---|
Secondary Ph+ acute lymphoblastic leukemia after temozolomide.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherap | 2005 |
Combi-targeting concept: an optimized single-molecule dual-targeting model for the treatment of chronic myelogenous leukemia.
Topics: Antineoplastic Agents; Cell Cycle; Cell Proliferation; Dacarbazine; DNA Damage; DNA-Binding Proteins | 2008 |
Antitumour imidazotetrazines XXVIII 3-methyladenine DNA glycosylase activity in cell lines sensitive and resistant to temozolomide.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Burkitt Lymphoma; Cell Line; Cell Survival; Chromato | 1992 |
Temozolomide induced differentiation of K562 leukemia cells is not mediated by gene hypomethylation.
Topics: Blotting, Northern; Cell Cycle; Cell Differentiation; Dacarbazine; DNA Damage; DNA, Neoplasm; Flow C | 1989 |